Cyclin K degrader 2

Cyclin K degrader 2 (compound S656) (0.5-10 µM; 5-14 days) exhibits significant growth inhibitory effects and antiproliferative activity in 56 primary AML samples; it displays a bimodal distribution of growth inhibition and cytotoxicity across 157 primary AML samples, and induces CRL4 complex-dependent cytotoxicity in OCI-AML1 (EKO) cells^[1].
Cyclin K degrader 2 (5-8 µM; 5 h) significantly degrades the Cyclin K protein in OCI-AML5 cells and 3 primary AML samples^[1].
Cyclin K degrader 2 (10 µM; 3 h) exhibits the ability to reduce fluorescence intensity and induce Cyclin K degradation in OCI-AML5 (G7 clone) cells expressing the cyclin K-eGFP reporter gene^[1].
Cyclin K degrader 2 (1-10 µM; 4-6 h) dose-dependently degrades Cyclin K and CDK12 proteins in OCI-AML5 cells, and significantly downregulates the mRNA expression of DNA damage response (DDR) genes^[1].
Cyclin K degrader 2 (1-5 µM; 4-24 h) induces G1-phase cell cycle arrest, dose-dependently triggers apoptosis, and depletes the anti-apoptotic protein Mcl-1 and the oncoprotein c-MYC in OCI-AML5 cells; it also induces γH2AX focus formation in U2OS cells^[1].
Cyclin K degrader 2 (0.625 nM-10 µM; 1 h) induces the protein-protein interaction between CDK12 and DDB1 in a dose-dependent manner in HEK293 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.